Biography

Andrew Clark, PhD, D(ABMM) is the Associate Director of Microbiology at Clements University Hospital at the University of Texas Southwestern Medical Center.  Dr. Clark received his undergraduate, masters, and doctoral degrees in Microbiology at the University of Arizona, Tucson AZ.  Following completion of his graduate studies, he then completed a CPEP-accredited postdoctoral fellowship training program in Clinical and Public Health Microbiology at the National Institutes of Health in Bethesda, MD.  Dr. Clark is board certified in Medical and Public Health Microbiology by the American Board of Medical Microbiology.  His research and academic interests are focused on antimicrobial susceptibility testing in the clinical microbiology laboratory.  He is also interested in the pathophysiology and antimicrobial resistance of anaerobic bacteria, and the evaluation and implementation of novel diagnostic technologies.

Education

Undergraduate School
University of Arizona (2006)
Graduate School
University of Arizona (2009)
Graduate School
University of Arizona (2017)
Fellowship
National Institutes of Health (NIH) (2019)

Research Interest

  • Antimicrobial resistance mechanisms and pathophysiology of anaerobic bacteria
  • Antimicrobial susceptibility testing
  • Evaluation of diagnostic technologies and diagnostic test utilization in the clinical microbiology laboratory

Publications

Featured Publications LegendFeatured Publications

Manual Reading of Sensititre? Broth Microdilution System Panels Improves Accuracy of Susceptibility Reporting for Polymyxin Antibiotics.
Bellerose MM, Clark AE, Youn JH, Weingarten RA, Crooks CM, Dekker JP, Frank KM, J Clin Microbiol 2021 Jun JCM0033221
Serological Response in Lung Transplant Recipients after Two Doses of SARS-CoV-2 mRNA Vaccines.
Narasimhan M, Mahimainathan L, Clark AE, Usmani A, Cao J, Araj E, Torres F, Sarode R, Kaza V, Lacelle C, Muthukumar A, Vaccines (Basel) 2021 Jun 9 7
Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative IgG and IgM Assays among Infected, Recovered, and Vaccinated Groups.
Narasimhan M, Mahimainathan L, Araj E, Clark AE, Markantonis J, Green A, Xu J, SoRelle JA, Alexis C, Fankhauser K, Parikh H, Wilkinson K, Reczek A, Kopplin N, Yekkaluri S, Balani J, Thomas A, Singal AG, Sarode R, Muthukumar A, J Clin Microbiol 2021 06 59 7 e0038821
Expanding COVID-19 Vaccine Availability: Role for Combined Orthogonal Serology Testing (COST).
Narasimhan M, Mahimainathan L, Araj E, Clark AE, Wilkinson K, Yekkaluri S, Tiro J, Lee FM, Balani J, Sarode R, Singal AG, Muthukumar A, Vaccines (Basel) 2021 Apr 9 4
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Screening With Specimen Pools: Time to Swim, or Too Deep for Comfort?
Clark AE, Lee FM, Clin Infect Dis 2020 Sep
Saliva for use with a point of care assay for the rapid diagnosis of COVID-19.
SoRelle JA, Mahimainathan L, McCormick-Baw C, Cavuoti D, Lee F, Thomas A, Sarode R, Clark AE, Muthukumar A, Clinica chimica acta; international journal of clinical chemistry 2020 Sep
Laboratory-developed test regulation and the immunocompromised patient: uncertainty ahead.
Clark AE, Levy J, Lee FM, Curr Opin Infect Dis 2020 08 33 4 304-311
Diagnostic Performance of a Rapid Point of Care Test for SARS-CoV-2 in an Urban ED Setting.
McDonald S, Courtney DM, Clark AE, Muthukumar A, Lee F, Balani J, Mahimainathan L, Bararia A, Oliver D, Sarode R, Diercks D, Acad Emerg Med 2020 Jun
Matrix-Assisted Laser Desorption Time of Flight Mass Spectrometry.
Wolk DM, Clark AE, Clin. Lab. Med. 2018 09 38 3 471-486
An Engineered Synthetic Biologic Protects Against Clostridium difficile Infection.
Vedantam G, Kochanowsky J, Lindsey J, Mallozzi M, Roxas JL, Adamson C, Anwar F, Clark A, Claus-Walker R, Mansoor A, McQuade R, Monasky RC, Ramamurthy S, Roxas B, Viswanathan VK, Front Microbiol 2018 9 2080

Professional Associations/Affiliations

  • American Society for Microbiology (2013)